Copyright investors
Intellia Therapeutics (NTLA) saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 67 to 71. IBD's unique RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks compares to other publicly traded companies. Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating of above 80 in the early stages of their moves. See if Intellia Therapeutics can continue to rebound and hit that benchmark. While the stock is not near an ideal buying range right now, see if it goes on to form and break out of a proper base. Intellia Therapeutics showed 0% EPS growth in the latest quarterly report, while sales growth came in at 105%. The company is expected to report its latest performance numbers on or around Nov. 6. The company earns the No. 360 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals (AUPH), Krystal Biotech (KRYS) and Travere Therapeutics (TVTX) are among the top 5 highly rated stocks within the group. This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
